Selinexor

XPOVIO®

Verified

Overview

Selinexor (Xpovio®) is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. Xpovio blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell. The forced nuclear retention of these proteins can counteract a multitude of the oncogenic pathways that, unchecked, allow cancer cells with severe DNA damage to continue to grow and divide in an unrestrained fashion.

Selinexor is an oral drug approved for use in combination with dexamethasone by relapsed or refractory myeloma patients who have received at least 4 prior therapies and who are resistant to at least 2 proteasome inhibitors, at least 2 immunomodulatory drugs, and to an anti-CD38 monoclonal antibody.

SparkCures ID 128
Developed By Karyopharm Therapeutics
Brand Name Xpovio®
Generic Name Selinexor
Additional Names KPT-330
Treatment Classifications
Tags
  • Published Results

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Published Results

Phase 3 BOSTON Study Meets Primary Endpoint with Significant Incease in Progression-Free Survival

March 10, 2020

  • Combination of Once-Weekly XPOVIO® (selinexor), Once-Weekly Velcade® (bortezomib) plus Dexamethasone (SVd) Results in Statistically Significant Reduction in the Risk of Disease Progression or Death Compared to Standard Twice-Weekly Velcade® plus Dexamethasone (Vd) Regimen
  • The BOSTON study met its primary endpoint of a statistically significant increase in progression-free survival (PFS).
  • The median PFS in the SVd arm was 13.93 months compared to 9.46 months in the Vd arm, representing a 4.47 month (47%) increase in median PFS (hazard ratio=0.70; p=0.0066). There were no new safety signals on the SVd arm and there was no imbalance in deaths between the two arms in the study.

Resources

SparkCures Verified

SparkCures is working closely with Karyopharm Therapeutics to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.

Learn more about how we work with industry partners